April 2010
Pharmaceutical Representative;Apr2010, Vol. 40 Issue 4, p10
The article offers information on drug testing studies. It says that Clabridine treatment for multiple sclerosis lowers annualized rate of relapse than in the placebo group with 0.14 and 0.15 vs, 0.33. Phase III study of SUN 1064 or sunitinib malate in advanced breast cancer did not show statistically significant improvement in progression-free survival compared to docetaxel alone. Multimeric-001 Universal Influenza Vaccine completed the second phase of its clinical trial.


Related Articles

  • Adverse Reaction Research.  // Reactions Weekly;11/17/2012, Issue 1428, p4 

    The article reports on a clinical trial data on the safety of dalfampridine, Ampyra, which was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

  • Dirucotide Data Show 'Nice Signal' Despite Miss.  // Bioworld Week;2/9/2009, Vol. 17 Issue 6, p2 

    The article reports on the determination of BioMS Medical Corp. in Edmonton, Alberta, despite its dirucotide data failure. According to the article, the company fell down for about 30.3% due to its relapse rate failure to its Phase II study on patients with multiple sclerosis (MS). However, the...

  • Best of the medical press. Marks, Roberta G. // RN;Feb82, Vol. 45 Issue 2, p13 

    Presents an update on medical studies as of February 1982. Impact of intrathecal interferon on multiple sclerosis patients; Effect of influenza vaccination on the liver's metabolism of various drugs; Effects of pregnant women's alcohol consumption on the fetus.

  • Promising results in early Antegren trial.  // Inside MS;Winter2002, Vol. 20 Issue 1, p36 

    Reports on the result of an early double-blind clinical trial of Antegren as announced at the 7th Congress of the European Committee on Treatment and Research in Multiple Sclerosis on September 15, 2001. Number of multiple sclerosis patients who participated in the trial; Effects of Antegren;...

  • One face behind the numbers. Yusuf, Katharine // American Journal of Health-System Pharmacy;11/1/2009, Vol. 66 Issue 21, p1955 

    A personal narrative is presented which explores the author's experience of participating in a clinical trial to cure her multiple sclerosis.

  • FTY720 (Fingolimod) als neue Therapiemöglichkeit der Multiplen Sklerose. Klatt, J.; Hartung, H.-P.; Hohlfeld, R. // Der Nervenarzt;Oct2007, Vol. 78 Issue 10, p1200 

    All currently available therapeutic options for multiple sclerosis have to be administered parenterally. Several oral substances are currently in the late clinical development stage. One of them, FTY720 (also known as fingolimod) is highlighted in this review. The biological effects of FTY720...

  • Immunosuppressive Agents in Multiple Sclerosis Neuhaus, Oliver; Kieseier, Bernd C.; Hartung, Hans-Peter // Neurotherapeutics;Oct2007, Vol. 4 Issue 4, p654 

    Summary: Immunosuppressive agents have been used in multiple sclerosis (MS) for decades. The approval of several immunomodulatory agents against MS beginning in the 1990s, whose putative mechanisms of action appeared “more MS-specific,” curtailed the importance of immunosuppressants,...

  • Serono and Ivax announce positive trials of oral MS drug.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p7 

    Reports on the positive results from two clinical trials of Serono Inc. and Ivax Corp.'s oral cladribine for the treatment of multiple sclerosis. Role of the pharmaceutical companies in the development of oral cladribine following the signing of a global agreement; Efficacy of the oral drug in...

  • Study shows benefit of switch to Teva's Copaxone in treatment of multiple sclerosis.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p12 

    Focuses on the clinical study of Copaxone, a treatment regimen for multiple sclerosis developed by Teva Pharmaceutical Industries Ltd. Presentation of the clinical study of Copaxone; Efficacy of Copaxone to treat multiple sclerosis; Indications for the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics